DSIP 10 mg

Dragon Pharma DSIP

DSIP 10 mg provides a research-grade dose of the remarkable neuropeptide first isolated from rabbit cerebral venous blood in the 1970s: Delta Sleep-Inducing Peptide. This naturally occurring nonapeptide (9 amino acids) has demonstrated a unique ability to regulate sleep architecture, specifically promoting the onset and duration of slow-wave delta sleep—the deepest and most restorative phase of the sleep cycle. Beyond its namesake function, DSIP exhibits a broad spectrum of neuroendocrine activities, including modulation of the hypothalamic-pituitary-adrenal (HPA) axis to reduce cortisol secretion, interaction with endogenous opioid systems, and potential influence on circadian rhythms. Its multifaceted action makes it a compelling subject for research into sleep disorders, stress adaptation, and recovery optimization.

For bodybuilders, athletes, and high-performance researchers in the USA, Dragon Pharma DSIP 10 mg offers a sophisticated tool for studying recovery enhancement and stress management. Intensive training creates physical stress that elevates cortisol, disrupts sleep, and can impede progress. Research into DSIP focuses on its potential to counteract these effects by promoting deeper, more restorative sleep and modulating the stress response. Improved sleep quality can enhance natural growth hormone secretion (which peaks during deep sleep), improve cognitive function, and accelerate physical recovery. Manufactured by Dragon Pharma under stringent quality control in certified European facilities, this 10 mg vial of lyophilized powder ensures researchers have access to a pure, stable, and precisely dosed compound for investigating sleep physiology and stress-related endpoints.

Key Benefits:

• Promotes Deep, Restorative Sleep: Specifically enhances slow-wave delta sleep, the most physically restorative sleep phase critical for recovery and growth hormone release.
• Modulates Stress Response: Helps regulate the HPA axis, potentially reducing excessive cortisol secretion associated with physical and psychological stress.
• Non-Sedating Sleep Regulation: Works through physiological pathways to normalize sleep architecture rather than acting as a conventional sedative, avoiding grogginess or dependency in research models.
• Endogenous Opioid Interaction: May interact with the body's natural opioid systems, contributing to pain modulation and a sense of well-being in study subjects.
• High-Concentration Research Formula: 10 mg per vial provides ample material for extended research protocols, including dose-response studies and combination research.

Each 2 mL vial contains 10 mg of highly pure Delta Sleep-Inducing Peptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) as a sterile lyophilized powder, synthesized using advanced solid-phase peptide synthesis under Dragon Pharma's exacting quality standards.

Product Specifications

Usage Guidelines

Research Application Notice: The following is based on scientific literature for educational context. Dragon Pharma DSIP 10 mg is a research chemical for laboratory study only, not for human consumption.

In experimental models, DSIP is reconstituted with bacteriostatic water. Given its primary research focus on sleep regulation, administration is typically timed for the evening, approximately 30-60 minutes before the subject's sleep period. Subcutaneous administration is common in preclinical research. For studies on acute stress adaptation, additional daytime dosing might be incorporated. Due to its short half-life, research often utilizes daily administration. Studies on sleep architecture typically employ polysomnography or similar monitoring to objectively measure changes in sleep stages, particularly increases in slow-wave delta sleep.

• Acute Sleep Optimization Study (1-2 weeks): Evening-only dosing protocol to investigate immediate effects on sleep onset, sleep architecture, and subjective sleep quality ratings.
• Chronic Stress & Recovery Protocol (4-8 weeks): May include both evening and occasional daytime dosing to study long-term HPA axis modulation, cortisol rhythms, and recovery markers in stressed models.

Post Cycle Therapy (PCT):

DSIP does not affect the HPTA, so traditional PCT with SERMs like Clomid is not applicable. The research consideration is maintaining healthy sleep architecture after cessation. Some protocols incorporate a gradual tapering of the dose. For ongoing sleep support research, natural supplements or other peptides like DSIP itself on an as-needed basis, or Semax for cognitive and neuroprotective support, could be explored.

Synergistic Research Combinations:

DSIP is often studied in combination with other recovery-enhancing compounds. For comprehensive sleep and recovery research, it can be paired with MK-677 (Ibutamoren), which also increases deep sleep and GH secretion. For stress adaptation studies, combining with adaptogens or Selank (an anxiolytic peptide) may be relevant. In performance research, it could be studied alongside Ipamorelin to enhance natural GH pulses during sleep. For overall wellness during intense training studies, GHK-Cu could be included for its tissue repair and anti-inflammatory properties.

Storage Instructions

Maintaining the stability of this neuropeptide is crucial for research integrity.

• Unreconstituted Powder: Store the sealed vial in a freezer at -20°C (-4°F) or colder for long-term stability. In this lyophilized state, DSIP remains stable for up to 24 months. Protect from light and moisture, and avoid repeated freeze-thaw cycles.
• After Reconstitution: Once reconstituted with bacteriostatic water, the solution must be refrigerated immediately at 2°C to 8°C (36°F to 46°F). The reconstituted solution is typically stable for research use for 3-4 weeks when refrigerated. For best results, use within 21 days. Never freeze the reconstituted liquid solution.
• Best Practices: Due to the peptide's sensitivity, reconstitute only the amount needed for the immediate research period. Use sterile technique to prevent bacterial contamination, which is particularly important for peptides administered near sleep periods in research models.